seroxatUSERgroup legacy; as the most dangerous Anti'd becomes worlds biggest $$

[Guest guest]

Wyeth (up $0.43 to $46.50, Research) bills its drug Effexor XR as the

world's top selling antidepressant. The numbers bear this out, but

they're slipping. Wyeth sold $861 million worth of the drug in the

third quarter of 2005, a 4 percent decline from the same period the

year before. Hazlett, analyst for Suntrust Humphrey,

said Effexor sales totaled $3.5 billion in 2005 worldwide. In its

most

recent financial report, Wyeth attributed the Effexor sales decline

to

a slowdown in the overall antidepressants market.

But for Wyeth, analysts see hope in an experimental antidepressant

called desvenlafaxine. Wyeth filed a new drug application for

desvenlafaxine to the FDA on Dec. 22 of last year. Bear Stearns

analyst Boris projects the drug will enter the market in 2007,

reaching $1 billion in annual sales by 2010. He adds that Wyeth is

well-positioned to " maximize [its] franchise " for antidepressants

before Effexor loses patent exclusivity in 2010.

http://money.cnn.com/2006/01/04/news/companies/antidepressants/?

cnn=yes

[Guest guest]

Wyeth (up $0.43 to $46.50, Research) bills its drug Effexor XR as the

world's top selling antidepressant. The numbers bear this out, but

they're slipping. Wyeth sold $861 million worth of the drug in the

third quarter of 2005, a 4 percent decline from the same period the

year before. Hazlett, analyst for Suntrust Humphrey,

said Effexor sales totaled $3.5 billion in 2005 worldwide. In its

most

recent financial report, Wyeth attributed the Effexor sales decline

to

a slowdown in the overall antidepressants market.

But for Wyeth, analysts see hope in an experimental antidepressant

called desvenlafaxine. Wyeth filed a new drug application for

desvenlafaxine to the FDA on Dec. 22 of last year. Bear Stearns

analyst Boris projects the drug will enter the market in 2007,

reaching $1 billion in annual sales by 2010. He adds that Wyeth is

well-positioned to " maximize [its] franchise " for antidepressants

before Effexor loses patent exclusivity in 2010.

http://money.cnn.com/2006/01/04/news/companies/antidepressants/?

cnn=yes